Dowling & Yahnke LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 77,155 shares of the company’s stock after selling 512 shares during the period. Johnson & Johnson makes up about 0.9% of Dowling & Yahnke LLC’s portfolio, making the stock its 25th biggest holding. Dowling & Yahnke LLC’s holdings in Johnson & Johnson were worth $9,362,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Tradition Capital Management LLC lifted its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Tradition Capital Management LLC now owns 41,550 shares of the company’s stock worth $5,324,000 after buying an additional 759 shares during the last quarter. Flossbach Von Storch AG raised its stake in Johnson & Johnson by 100.1% during the 1st quarter. Flossbach Von Storch AG now owns 2,318,450 shares of the company’s stock valued at $297,109,000 after purchasing an additional 1,159,690 shares during the last quarter. Miles Capital Inc. raised its stake in Johnson & Johnson by 8.0% during the 1st quarter. Miles Capital Inc. now owns 12,430 shares of the company’s stock valued at $1,593,000 after purchasing an additional 923 shares during the last quarter. ARGI Investment Services LLC raised its stake in Johnson & Johnson by 11.5% during the 1st quarter. ARGI Investment Services LLC now owns 12,692 shares of the company’s stock valued at $1,598,000 after purchasing an additional 1,308 shares during the last quarter. Finally, Mitchell Capital Management Co. raised its stake in Johnson & Johnson by 84.9% during the 1st quarter. Mitchell Capital Management Co. now owns 4,873 shares of the company’s stock valued at $624,000 after purchasing an additional 2,237 shares during the last quarter. Hedge funds and other institutional investors own 66.60% of the company’s stock.
Several equities analysts recently commented on JNJ shares. Raymond James upped their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Citigroup upped their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Finally, ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $142.54.
Shares of Johnson & Johnson stock opened at $142.57 on Wednesday. The firm has a market capitalization of $377.43 billion, a price-to-earnings ratio of 19.53, a price-to-earnings-growth ratio of 2.20 and a beta of 0.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.90 EPS. Analysts expect that Johnson & Johnson will post 8.16 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Dowling & Yahnke LLC Has $9.36 Million Stake in Johnson & Johnson (JNJ)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/11/07/dowling-yahnke-llc-has-9-36-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Understanding the different types of bonds
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.